Abstract
Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Current Molecular Medicine
Title:At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Volume: 13 Issue: 7
Author(s): B. B. Goulet, R. Kothary and R. J. Parks
Affiliation:
Keywords: Genetic disease, neuromuscular junction, pathogenesis, spinal muscular atrophy.
Abstract: Spinal muscular atrophy (SMA) is caused by mutations that reduce the level of the survival motor neuron protein (SMN) resulting in death of alpha-motor neurons, yet it is unclear why these cells are preferentially affected by a reduction in this ubiquitously-expressed protein. In mouse models of SMA, one of the earliest events detected is defects at the neuromuscular junction (NMJ). Although NMJs are established at a normal frequency, there are structural as well as functional perturbations and a lack of maturation of the primitive synapse. These early defects are followed by loss of the NMJ, denervation of the muscle and onset of muscle atrophy. In this review, we discuss our current understanding of the contribution of NMJ dysfunction in SMA disease pathogenesis, and also provide an overview of therapies currently under preclinical and clinical development for treatment of SMA.
Export Options
About this article
Cite this article as:
Goulet B. B., Kothary R. and Parks J. R., At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression, Current Molecular Medicine 2013; 13 (7) . https://dx.doi.org/10.2174/15665240113139990044
DOI https://dx.doi.org/10.2174/15665240113139990044 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery Diagnosed in Adulthood
Current Medical Imaging Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology How Does the Treadmill Affect Gait in Parkinsons Disease?
Current Aging Science Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Target Oxygen Levels and Critical Care of the Newborn
Current Pediatric Reviews MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Adrenomedullin-RAMP2 System in Cardiovascular Development and Homeostasis
Current Hypertension Reviews Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The Utility of Emerging Biomarkers and Imaging for Assessment of Cardiovascular Risk
Current Vascular Pharmacology Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies
Current Pharmaceutical Design Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Potential Triazole-based Molecules for the Treatment of Neglected Diseases
Current Medicinal Chemistry